373 related articles for article (PubMed ID: 22012070)
21. Additive effects of anticoagulants: recombinant human activated protein C and heparin or melagatran, in tissue factor-activated umbilical-cord plasma.
Koestenberger M; Gallistl S; Muntean W; Leschnik B; Fritsch P; Cvirn G
Thromb Haemost; 2005 Jul; 94(1):69-74. PubMed ID: 16113786
[TBL] [Abstract][Full Text] [Related]
22. Heparin chain-length dependence of factor Xa inhibition by antithrombin in plasma.
Rezaie AR
Thromb Res; 2007; 119(4):481-8. PubMed ID: 16515805
[TBL] [Abstract][Full Text] [Related]
23. Differences in the clinically effective molar concentrations of four direct thrombin inhibitors explain their variable prothrombin time prolongation.
Warkentin TE; Greinacher A; Craven S; Dewar L; Sheppard JA; Ofosu FA
Thromb Haemost; 2005 Nov; 94(5):958-64. PubMed ID: 16363236
[TBL] [Abstract][Full Text] [Related]
24. The respective and combined anticoagulant effects of recombinant human activated protein C, melagatran and heparins using CAT.
Cimenti C; Koestenberger M; Leschnik B; Haidl H; Muntean W
Thromb Res; 2007; 119(3):361-7. PubMed ID: 16712904
[TBL] [Abstract][Full Text] [Related]
25. Extracellular histones increase plasma thrombin generation by impairing thrombomodulin-dependent protein C activation.
Ammollo CT; Semeraro F; Xu J; Esmon NL; Esmon CT
J Thromb Haemost; 2011 Sep; 9(9):1795-803. PubMed ID: 21711444
[TBL] [Abstract][Full Text] [Related]
26. The technique of measuring thrombin generation with fluorogenic substrates: 3. The effects of sample dilution.
De Smedt E; Wagenvoord R; Coen Hemker H
Thromb Haemost; 2009 Jan; 101(1):165-70. PubMed ID: 19132204
[TBL] [Abstract][Full Text] [Related]
27. Soluble thrombomodulin is antithrombotic in the presence of neutralising antibodies to protein C and reduces circulating activated protein C levels in primates.
Tanaka KA; Fernández JA; Marzec UM; Kelly AB; Mohri M; Griffin JH; Hanson SR; Gruber A
Br J Haematol; 2006 Jan; 132(2):197-203. PubMed ID: 16398653
[TBL] [Abstract][Full Text] [Related]
28. Edoxaban: Impact on routine and specific coagulation assays. A practical laboratory guide.
Douxfils J; Chatelain B; Chatelain C; Dogné JM; Mullier F
Thromb Haemost; 2016 Jan; 115(2):368-81. PubMed ID: 26510969
[TBL] [Abstract][Full Text] [Related]
29. Rivaroxaban pharmacodynamics in healthy volunteers evaluated with thrombin generation and the active protein C system: Modeling and assessing interindividual variability.
Siguret V; Abdoul J; Delavenne X; Curis E; Carlo A; Blanchard A; Salem JE; Gaussem P; Funck-Brentano C; Azizi M; Mismetti P; Loriot MA; Lecompte T; Gouin-Thibault I
J Thromb Haemost; 2019 Oct; 17(10):1670-1682. PubMed ID: 31215111
[TBL] [Abstract][Full Text] [Related]
30. Thrombomodulin improved liver injury, coagulopathy, and mortality in an experimental heatstroke model in mice.
Kawasaki T; Okamoto K; Kawasaki C; Sata T
Anesth Analg; 2014 May; 118(5):956-63. PubMed ID: 24781566
[TBL] [Abstract][Full Text] [Related]
31. The paradoxical antifibrinolytic effect of dabigatran and argatroban in the presence of soluble thrombomodulin is unrelated to protein C-dependent increase of thrombin generation.
Incampo F; Carrieri C; Semeraro N; Colucci M
Thromb Res; 2014 Nov; 134(5):1110-6. PubMed ID: 25193406
[TBL] [Abstract][Full Text] [Related]
32. Influence of recombinant hirudin and unfractionated heparin on thrombin and factor Xa generation in extrinsic and intrinsic activated systems.
Kaiser B; Fareed J; Hoppensteadt D; Birdsong B; Walenga JM; Markwardt F
Thromb Res; 1992 Jan; 65(2):157-64. PubMed ID: 1579892
[TBL] [Abstract][Full Text] [Related]
33. Large inter-individual variation of the pharmacodynamic effect of anticoagulant drugs on thrombin generation.
Bloemen S; Hemker HC; Al Dieri R
Haematologica; 2013 Apr; 98(4):549-54. PubMed ID: 23100275
[TBL] [Abstract][Full Text] [Related]
34. Anticoagulant action of melagatran: a comparison between neonates and adults using calibrated automated thrombography (CAT).
Cvirn G; Cimenti C; Kutschera J; Ferstl U; Wagner T; Muntean W; Jurgens G; Gallistl S; Koestenberger M
Eur J Pediatr; 2007 May; 166(5):427-31. PubMed ID: 17047995
[TBL] [Abstract][Full Text] [Related]
35. Measurement of antithrombin activity by thrombin-based and by factor Xa-based chromogenic substrate assays.
Beeck H; Nagel D; Pindur G; Scharrer I; Preiss A; Seiler D; Hellstern P
Blood Coagul Fibrinolysis; 2000 Mar; 11(2):127-35. PubMed ID: 10759005
[TBL] [Abstract][Full Text] [Related]
36. Protein C inhibitor acts as a procoagulant by inhibiting the thrombomodulin-induced activation of protein C in human plasma.
Elisen MG; von dem Borne PA; Bouma BN; Meijers JC
Blood; 1998 Mar; 91(5):1542-7. PubMed ID: 9473218
[TBL] [Abstract][Full Text] [Related]
37. Thrombomodulin alfa attenuates the procoagulant effect and cytotoxicity of extracellular histones through the promotion of protein C activation.
Osada K; Minami T; Arioka T; Sakai T; Tawara S; Kawasaki K; Fareed J; Matsuzaki O
Thromb Res; 2017 Dec; 160():51-57. PubMed ID: 29101790
[TBL] [Abstract][Full Text] [Related]
38. Apixaban, a direct factor Xa inhibitor, inhibits tissue-factor induced human platelet aggregation in vitro: comparison with direct inhibitors of factor VIIa, XIa and thrombin.
Wong PC; Jiang X
Thromb Haemost; 2010 Aug; 104(2):302-10. PubMed ID: 20589316
[TBL] [Abstract][Full Text] [Related]
39. Calibrated automated thrombin generation measurement in clotting plasma.
Hemker HC; Giesen P; Al Dieri R; Regnault V; de Smedt E; Wagenvoord R; Lecompte T; Béguin S
Pathophysiol Haemost Thromb; 2003; 33(1):4-15. PubMed ID: 12853707
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of endothelial cell-mediated generation of activated protein C by direct and antithrombin-dependent thrombin inhibitors.
Linder R; Frebelius S; Jansson K; Swedenborg J
Blood Coagul Fibrinolysis; 2003 Feb; 14(2):139-46. PubMed ID: 12632023
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
